US Patent

US8501760 — Pharmaceutical compositions comprising nilotinib or its salt

Formulation · Assigned to Novartis AG · Expires 2026-07-18 · 0y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition, specifically capsules, containing nilotinib or its salt with one or more acceptable excipients.

USPTO Abstract

A pharmaceutical composition, especially capsules, comprising granules containing nilotinib or a salt thereof with at least one pharmaceutically acceptable excipient. The granules may be produced by a wet granulation process.

Drugs covered by this patent

nilotinib-hydrochloride (Nilotinib Hydrochloride) · Jan Beumer

Patent Metadata

Patent number: US8501760
Jurisdiction: US
Classification: Formulation
Expires: 2026-07-18
Drug substance claim: No
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.